Explainer

RSV risk factors: who is at risk for severe RSV

RSV usually causes a mild cold, but it can cause serious lung infections in babies, older adults and people with some medical conditions. Here is what MedlinePlus and the CDC's vaccine advisers (ACIP) say about who is at higher risk and who is advised to get RSV protection.

Last reviewed: By the uncovermyrisk.com editorial team Educational only, not medical advice.

Watch young babies closely.In very young infants, the only signs of RSV may be irritability, being less active and trouble breathing (MedlinePlus). If a baby or anyone else has trouble breathing, get medical care right away.

What RSV is

Respiratory syncytial virus (RSV) is a common respiratory virus. It usually causes mild, cold-like symptoms, but it can cause serious lung infections, especially in infants, older adults and people with serious medical problems (MedlinePlus). In the US, RSV season is usually fall through spring (MedlinePlus).

RSV spreads through coughs and sneezes, direct contact such as kissing the face of a child who has RSV, and touching a surface with the virus on it and then your mouth, nose or eyes (MedlinePlus). CDC estimates that RSV was linked to 190,000 to 350,000 hospital stays and 10,000 to 23,000 deaths in the US from July 2024 to June 2025 (CDC 2026).

Who is at risk for severe RSV

RSV can affect people of all ages, and nearly all children have had it by age 2 (MedlinePlus). These groups are more likely to get very sick:

Symptoms

Symptoms usually start about 4 to 6 days after infection and tend to come in stages rather than all at once (MedlinePlus):

In people at high risk, RSV can lead to bronchiolitis (swelling of the small airways in the lungs) or pneumonia (MedlinePlus). Most infections go away on their own in a week or two, and there is no specific treatment for RSV. Do not give aspirin to children, and do not give cough medicine to children under 4 (MedlinePlus).

Who CDC advises to get RSV protection

Adults. A single dose of RSV vaccine is recommended for all adults 75 and older, and for adults 50 to 74 who are at increased risk for severe RSV (CDC 2026). Adults who have already had an RSV vaccine should not get another dose (ACIP 2024).

Babies. CDC advises that all infants be protected against serious RSV lung infection with one of three product options (ACIP 2025):

The two antibody shots are for babies younger than 8 months who are born during or entering their first RSV season and who are not protected by the pregnancy vaccine (ACIP 2025).

No one product is preferred, and most babies do not need both the pregnancy vaccine and an antibody shot (ACIP 2025). Children 8 to 19 months old at increased risk can get nirsevimab before their second RSV season (ACIP 2023 (nirsevimab)).

Recommendations can change. Your doctor, pharmacist or your baby's doctor can tell you what fits you now.

Everyday steps that lower the risk of spread

Common questions

What are the RSV risk factors in adults?

Age 75 and older, and for adults 50 to 74, conditions that raise the risk of severe RSV (CDC 2026), such as COPD, asthma, heart failure, coronary artery disease, diabetes, chronic kidney disease, a weakened immune system, frailty or living in a nursing home (ACIP 2023).

How long is someone with RSV contagious?

Usually for 3 to 8 days. Infants and people with weakened immune systems can sometimes spread the virus for as long as 4 weeks (MedlinePlus).

My baby has no health problems. Are they still at risk?

Yes. Most babies hospitalized with RSV have no known risk factor, which is why CDC advises protection for all infants (ACIP 2025).

Related guide: measles risk factors, including whether a childhood MMR vaccine still protects you.

Related guide: who is at high risk for flu complications, with the warning signs that need care right away.

Related guide: pneumonia risk factors, including who is most at risk of serious pneumonia.

Sources

  1. MedlinePlus, National Library of Medicine. Respiratory Syncytial Virus Infections. Health topic page, last updated May 5, 2025. medlineplus.gov/respiratorysyncytialvirusinfections.html
  2. Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801. doi:10.15585/mmwr.mm7229a4. PMCID PMC10360650. CDC, public domain. Introduction and Clinical Guidance. pmc.ncbi.nlm.nih.gov/articles/PMC10360650/
  3. Britton A, Roper LE, Kotton CN, et al. Use of Respiratory Syncytial Virus Vaccines in Adults Aged 60 Years and Older: Updated Recommendations of the Advisory Committee on Immunization Practices, United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(32):696-702. doi:10.15585/mmwr.mm7332e1. PMID 39146277. Abstract. pubmed.ncbi.nlm.nih.gov/39146277/
  4. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920-925. doi:10.15585/mmwr.mm7234a4. PMCID PMC10468217. CDC, public domain. Summary, RSV Among Infants and Young Children, and Box. pmc.ncbi.nlm.nih.gov/articles/PMC10468217/
  5. Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115-1122. doi:10.15585/mmwr.mm7241e1. PMCID PMC10578951. CDC, public domain. Summary. pmc.ncbi.nlm.nih.gov/articles/PMC10578951/
  6. Moulia DL, Link-Gelles R, Chu HY, et al. Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices, United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74(32):508-514. doi:10.15585/mmwr.mm7432a3. PMCID PMC12393692. CDC, public domain. Summary and Introduction. pmc.ncbi.nlm.nih.gov/articles/PMC12393692/
  7. Silk BJ, Prill MM, Winn AK, et al. Respiratory Virus Activity, United States, July 1, 2024-June 30, 2025. MMWR Morb Mortal Wkly Rep. 2026;75(6):77-84. doi:10.15585/mmwr.mm7506a2. PMCID PMC12919848. CDC, public domain. Abstract and Discussion. pmc.ncbi.nlm.nih.gov/articles/PMC12919848/

Written and maintained by the uncovermyrisk.com editorial team. We do not have a medical reviewer; every claim links to its primary source above. Last reviewed: 2026-11-06. Spotted an error? See About.